ANTIVASCULAR ULTRASOUND THERAPY EXTENDS SURVIVAL OF MICE WITH IMPLANTED MELANOMAS

被引:43
|
作者
Wood, Andrew K. W. [2 ]
Schultz, Susan M. [1 ]
Lee, William M-F. [3 ]
Bunte, Ralph M. [4 ]
Sehgal, Chandra M. [1 ]
机构
[1] Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA
[3] Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Univ Lab Anim Resources, Philadelphia, PA 19104 USA
关键词
Low-intensity ultrasound therapy; Ultrasound contrast agent; Antivascular; Angiogenesis; Melanoma; COMBRETASTATIN A4 PHOSPHATE; VASCULAR DISRUPTING AGENTS; PHYSIOTHERAPY ULTRASOUND; FOCUSED ULTRASOUND; TARGETING AGENT; MURINE TUMOR; PHARMACOKINETICS; DMXAA;
D O I
10.1016/j.ultrasmedbio.2010.02.001
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
The goal of this murine investigation was to evaluate the effect of an antivascular ultrasound treatment on the growth of an implanted melanoma and the consequent survival rate. After the intravenous injection of 0.2 mL ultrasound contrast agent (Definity), therapy (n = 15) was performed on 1-mL tumors for 3 min with low-intensity continuous ultrasound (3 MHz; 2.4 +/- 0.1 W.cm(-2) [I-SATA]); control mice (n = 17) received a sham treatment. Mice were euthanized once the tumor had reached 3 mL, and then survival percentage vs. time curves were plotted. The median survival time (time for tumor to reach 3 mL) for the treated group was 23 d and for the control group was 18 d; the difference was statistically significant (p <= 0.0001). Antivascular ultrasound therapy reduced the growth rate of an implanted melanoma and increased survival time. The ultrasound therapy provides a further example of tumor vascular disruption, and its future clinical potential should be investigated. (E-mail: sehgalc@uphs.upenn.edu) (c) 2010 World Federation for Ultrasound in Medicine & Biology.
引用
收藏
页码:853 / 857
页数:5
相关论文
共 21 条
  • [21] AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice
    Kujala, Anni
    Valkonen, Elina
    Sallinen, Hanna
    Tuppurainen, Laura
    Laakso, Hanne
    Yla-Herttuala, Elias
    Liimatainen, Timo
    Kujala, Jouni
    Jokelainen, Otto
    Sironen, Reijo
    Anttila, Maarit
    Yla-Herttuala, Seppo
    FRONTIERS IN MEDICINE, 2022, 9